SAN FRANCISCO, CA--(Marketwire - September 13, 2011) - SteadyMed Therapeutics, Inc. today announced that Jonathan M. Rigby has been appointed as President, Chief Executive Officer and a member of the Board of Directors. Mr. Rigby succeeds Yossi Aldar, who has led the company since its founding, and who will remain at the company as Chief Operating Officer.
"I am delighted to welcome Jonathan at this pivotal time as we advance towards our goal of becoming a commercially focused drug delivery therapeutics company. Jonathan's deep appreciation for both the critical elements required to execute on our strategy, as well as a proven track record in the financing and commercialization of drug delivery enabled products will be a great asset," said Aldar. "I look forward to Jonathan's leadership at this exciting time for SteadyMed."
Mr. Rigby, previously served as Co-Founder and Vice President of San Diego-based Zogenix, Inc., where he played a key role in both business development and in spearheading the financing activities that led to the company developing and launching the world's first and only prefilled, disposable, needle free drug delivery injection system for the treatment of acute migraines in both the United States and Europe. Mr. Rigby brings to SteadyMed over 20 years in the pharmaceutical, medical device and drug delivery industries with companies such as Merck, BMS, Profile Therapeutics (now Phillips) and Aradigm Corporation. He holds a Bachelor of Science with Honors in Biological Sciences from The University of Sheffield, United Kingdom and a Masters of Business Administration from Portsmouth University, United Kingdom.
"I am pleased to be joining SteadyMed at such an important phase of its development," said Rigby. "Our prefilled, disposable, PatchPump® subcutaneous delivery platform is well-positioned for SteadyMed to become the market leader as we develop our own high value, low risk commercial products, along with partnering with other pharma companies to provide solutions for their drug delivery needs. Our PatchPump® platform has great potential to impact the delivery of biopharmaceutical drugs to patients in the most size and cost efficient manner available. What brought me to SteadyMed is the tremendous opportunity this company and its products have to change the lives of patients with debilitating diseases by bringing better delivery systems to those who need them, while overcoming the delivery challenges posed by these valuable therapies."
"Jonathan's leadership will be instrumental in the company's transition from a research and development entity to a fully commercial drug delivery therapeutics leader," commented Yehuda Zisapel, Chairman of the Board of SteadyMed. "The Board and I are looking forward to his contributions as both our CEO and as a member of the Board of Directors. We believe that Jonathan perfectly complements the passion and commitment of SteadyMed's existing senior leadership team and employees, and feel he will be instrumental in delivering results that will drive value through innovation."
SteadyMed Therapeutics, Inc., with offices in San Francisco, CA and Tel-Aviv, Israel, is a private, venture funded drug delivery therapeutics company engaged in the development for commercialization of its prefilled, size efficient and disposable PatchPump® technology.
The company's range of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner.
The company is leveraging the sustainable cost and technological competitive advantages of its PatchPump platform to create a family of products that benefit patients in target markets, which represent the highest value to risk ratios.